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By Gan Zhao1, John P Vasilakos2, Debra Tross1, Dmitri Smirnov2 and Dennis M Klinman1*Abstract
Background: The TLR7/8 agonist 3M-052 and the TLR9 agonist CpG ODN both trigger innate immune responses
that support the induction of tumor-specific immunity. Previous studies showed that these agonists used individually
could improve the survival of mice challenged with small tumors but were of limited therapeutic benefit against large/
advanced tumors.
Methods: Normal mice were challenged with syngeneic tumors. Once these tumors reached clinically detectable size
(500–800 mm3) they were treated by intra-tumoral injection with 3M-052 and/or CpG ODN. Anti-tumor immunity and
tumor growth were evaluated.
Results: The co-delivery of agonists targeting TLRs 7, 8 and 9 increased the number and tumoricidal activity of
tumor infiltrating CTL and NK cells while reducing the frequency of immunosuppressive MDSC. The combination
of 3M-052 plus CpG ODN (but not each agent alone) eradicated large primary tumors and established long-term
protective immunity.
Conclusion: The combination of agonists targeting TLRs 7/8 and 9 represents a significant improvement in
cancer immunotherapy.
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Toll-like receptors (TLRs) comprise a family of highly
conserved germline-encoded pattern recognition recep-
tors that detect pathogen-associated molecular patterns
(PAMPs) expressed by a variety of infectious microor-
ganisms [1]. The ability of TLRs to trigger the innate im-
mune system and bolster adaptive immunity against
antigens expressed by pathogens and tumors is well
established [2,3]. At least 13 different TLRs have been iden-
tified in mammals, with TLRs 7, 8, and 9 being similar in
their recognition of nucleic acid motifs and expression
within endosomal compartments [1,4,5].
Studies show that TLR7 is primarily expressed by
plasmacytoid dendritic cells (pDC), TLR8 by mono-
cytes, monocyte-derived (m)DCs, macrophages and
Langerhans cells, and TLR9 by DCs, B cells, mono-
cytes and mast cells [6-9]. Synthetic agonists designed
to stimulate TLR7 typically trigger TLR8 as well and* Correspondence: klinmand@mail.nih.gov
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unless otherwise stated.induce the secretion of IL-12 and TNFα by mDCs and/
or pDCs [10,11]. Many TLR7/8 agonists also enhance
the expression of co-stimulatory molecules and the mi-
gration of DCs, thereby facilitating the induction of
Th1 immune responses [12,13]. Synthetic oligonucleo-
tides that express CpG motifs trigger TLR9 and elicit a
Th1-dominated immune response characterized by the
production of pro-inflammatory cytokines (including
IL-12, IFNα, and TNFα) and the up-regulation of co-
stimulatory (CD80 and CD86) and MHC class I and II
molecules [14-16].
The anti-tumor activity of TLR agonists targeting
TLRs 7, 8 and 9 has generally been explored by deliver-
ing them systemically to mice with relatively small tu-
mors (typically ≤200 mm3) [17]. While effective against
tumors <300 mm3, TLR-based therapy of large tumors
(>500 mm3) has been much harder to achieve [18-21]. A
growing body of evidence suggests that the efficacy of
TLR agonists might be improved by i) using them in
combination and ii) injecting them directly into the cancer-
ous tissue [18,22]. Large tumors are commonly infiltratedan Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Effect of TLR agonists on the growth of small tumors.
105 CT26 colon carcinoma cells were implanted into the flank of
syngeneic BALB/c mice. When the tumors reached ≈ 200 mm3 in
volume they were injected with 100 μg of CpG or control ODN and/
or 50 μg of 3M-052 or 3M control. Each treatment was repeated
2 days later. Data show the change in tumor volume (mean + SE) of
6–8 mice from 2 independent experiments. *, p < 0.05; **, p <0.01
compared with the control group.
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tumor responses. Local delivery of TLR agonists appears to
interfere with the function of toleragenic cells in the tumor
microenvironment. In this context, intra-tumoral injection
of CpG ODN reduced the number and suppressive activity
of tumor infiltrating MDSC [22]. Based on preliminary
findings, we hypothesized that a combination of agonists
targeting TLRs 7, 8 and 9 might be highly effective against
established tumors. Unfortunately, the physicochemical
characteristics of first generation TLR7/8 agonists resulted
in a short in vivo half-life that reduced their activity when
co-delivered with CpG ODN.
In the current work, this limitation was overcome by
studying a novel TLR7/8 agonist (3M-052) modified
with a lipophylic tail that persists in vivo at high levels
for at least 24 hr after administration [23] (Additional file
1: Figure S1 and Additional file 2: Table S1). Results
show that the combination of 3M-052 plus CpG ODN
significantly increases CTL activity and Th1 cytokine
production while down-regulating the activity of im-
munosuppressive MDSC. Although neither CpG ODN
nor 3M-052 alone were effective against large tumors,
the combination was highly active and mediated
tumor eradication and the establishment of long-term
immunity.
Results
Effect of TLR agonists on the growth of small tumors
CT26 colon cancer cells were implanted subcutaneously
into the flank of syngeneic BALB/c mice. When these
tumors reached 200 mm3 in volume, 100 μg of ODN
and/or 50 μg of 3M-052 was injected intra-tumorally
and the procedure repeated 2 days later. Tumors in un-
treated mice proliferated rapidly and increased in size by
5-fold within 2 wk (Figure 1). The rate of proliferation
was significantly reduced by treatment with either CpG
ODN or 3M-052, although the tumors persisted. In con-
trast, animals treated with a combination of CpG ODN
plus 3M-052 completely rejected their tumors (p < 0.01;
Figure 1).
Effect of TLR agonists on the frequency of tumor
infiltrating mMDSC, NK and CD8 T cells
Immune cells in the tumor microenvironment pro-
foundly influence the success of immunotherapy. A sin-
gle cell suspension was prepared from tumor samples,
and the frequency of various immune subsets evaluated
by FACS (Additional file 3: Figure S2). The number of
mMDSC is considered an important marker of immune
suppression, as these cells suppress the tumoricidal ac-
tivity of CTL and NK cells. Consistent with previous
reports, the frequency of Gr1+CD11b+ mMDSC was
significantly elevated in mice bearing CT26 tumors
(Figure 2). Treatment with either CpG ODN or 3M-052 alone reduced the number of mMDSC infiltrating
the tumor site by ≈ 50% (p <0.05). The combination of
these two agonists resulted in a nearly 90% reduction
in mMDSC frequency (p <0.01, Figure 2). This effect
was detectable by 1 day after the second treatment.
Previous studies showed that the infiltration of NK
and CD8 T cells into the tumor microenvironment was
associated with improved host survival [22]. The effect
of TLR agonist treatment on the frequency of tumorici-
dal cells was therefore analyzed. The number of NK cells
was ≈ 25% higher in mice treated with 3M-052 or CpG
ODN when compared to untreated controls (p <0.05,
Figure 2). This increase was magnified in mice treated
with the combination of both TLR agonists. By compari-
son, while CpG ODN or 3M-052 alone increased CD8 T
cell frequency by approximately 2-fold, the combination
of both agonists synergistically increased CD8 T cell
numbers by >5-fold (p <0.05, Figure 2). No effect on the
frequency of Foxp3+ Treg was observed (Additional
file 4: Figure S3).
Two experiments were performed to explore the func-












































































Figure 2 Effect of TLR agonists on the frequency of tumor
infiltrating MDSC, NK and CD8 T cells. Mice were treated as
described in Figure 1. The frequency of tumor-infiltrating MDSC,
NK and CD8+ T cells was determined one day after the second
treatment. Results show the mean + SD of each cell type as a percentage
of total CD45+ tumor infiltrating cells analyzed independently in 6 mice
from 2 independent experiments. *, p < 0.05; **, p <0.01.
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with the CT26-derived AH-1 tumor peptide. To monitor
CTL activity, the frequency of IFNγ secreting cells was
determined by ELIspot assay. Consistent with changes in
the frequency of CD8 T cells noted above, the number
of cells stimulated by AH-1 peptide to produce IFNγ
was >8-fold higher in mice treated with CpG ODN plus
3M-052 than in controls by 3 days post treatment (p <
0.001, Figure 3). To evaluate the relevance of these T
cells in vivo, mice that had been challenged with tumor








































































Figure 3 Effect of TLR agonists on tumor-specific CTL. CT26
tumors were implanted into BALB/c mice as described in Figure 1.
Spleen cells and tumor infiltrating lymphocytes were isolated one
day after the second treatment, stimulated ex vivo with AH-1
peptide, and monitored for IFNγ secretion by ELIspot assay.
Results represent the mean + SD of 6 mice from 2 independent
experiments. *, p < 0.05; **, p <0.01.
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Figure 4, protection was abrogated by depletion of
CD8+ but not CD4+ T cells, indicating that tumor-
specific CD8 T cells were critical mediators of tumor
immunity.
Effect of TLR agonists on gene expression in the tumor
microenvironment
Treatment with CpG ODN and/or 3M-052 led to a sig-
nificant changes in the frequency of CD8 T cells, NK
cells and MDSC (Figure 2). To evaluate the activity of
these cells, the expression of genes associated with their
immunological function was examined by qPCR. The
genes selected to evaluate CD8 and NK cell responses
were IL-12 and IFNγ (which contribute to the induction
and maintenance of immunity) and granzyme B (which
mediates their cytotoxicity) [24-26]. As seen in Table 1,
cells isolated from the tumor of mice treated with either
CpG ODN or 3M-052 had higher levels of expression of
IL-12, IFNγ and granzyme B than tumor infiltrating cells
from untreated mice (p <.05). In animals treated with a
combination of both agonists, mRNA levels were signifi-
cantly higher when compared to either agonist alone
(see Table legend). This effect was additive for IL-12 and
IFNγ and supra-additive for Granzyme B.
It is well established that the mechanism by which MDSC
suppress T cell cytotoxicity in the tumor microenvironment
is mediated by the production of L-arginine via arginase-1
and the release of iNOS [27,28]. The expression of Arg1
and Nos2 by tumor infiltrating immune cells was therefore
evaluated by qPCR. Results show that 3M-052 but not CpG
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Figure 4 Effect of depleting CD8 T cells on immune mediated
protection. CT26 tumors were implanted into BALB/c mice and
treated with 100 μg of CpG and 50 μg of 3M as described in
Figure 1. The effect of depleting CD4 or CD8 T cells on tumor
growth was determined as described in the Methods section. Data
show the change in tumor volume (mean + SE) of 5 mice/group.
*, p < 0.05; **, p <0.01 compared with the control group.these immunosuppressive agents (Table 1). The combin-
ation of CpG ODN plus 3M-052 further reduced expres-
sion levels of both genes, an effect culminating in a nearly
90% reduction in Nos2 mRNA (p <.05).
Immune suppression in the tumor microenvironment
can take many forms. One metric of the down-regulation
of CTL activity is the expression of CTLA-4 by T cells and
another is the production of the immunoinhibitory
molecule TGFβ. CTLA-4, a homologue and antagonist
of CD28 [29,30], acts as negative regulator of T cell
activation by depriving them of CD28-mediated co-
stimulation [30,31]. On the other hand, TGFβ sup-
presses both innate and adaptive immune responses in
the tumor microenvironment. CTL-mediated tumor
elimination is thus reduced by the presence of TGFβ
[32,33]. As both 3M-052 and CpG ODN tend to reduce
the level of immune suppression in the tumor micro-
environment, their effect on CTLA-4 and TGFβ ex-
pression was examined. When compared to cells
isolated from tumors treated with PBS, both TLR ago-
nists mediated a significant reduction in the level of
expression of these genes (Table 1). The combination
of both 3M-052 and CpG ODN was even more effective
(p < .05).
Effect of TLR agonists on the growth of large tumors
To evaluate the effect of TLR agonists on tumors of
clinically relevant size, CT26 cancer cells were implanted
as described above and treatment initiated only after the
resultant tumors reached ≈ 800 mm3 in volume. Mice
were then injected intra-tumorally twice weekly for one
month with 200 μg of CpG ODN and/or 100 μg of 3M-
052. Tumors in untreated mice proliferated rapidly over
this period, reaching a volume of >2,000 mm3 within
10 days (mandating their sacrifice as per ACUC guide-
lines, Figure 5). While both CpG ODN and 3M-052
therapy slowed tumor growth and prolonged survival,
tumors in all animals reached 2,000 mm3 by 3 wk after
the initiation of treatment (Figure 5). In contrast, 87%
(13/15) of the mice treated with the combination of
CpG ODN plus 3M-052 in 3 independent experiments
completely rejected their tumors (p < 0.01; Figure 5).
To verify the utility of this combination against even
more aggressive tumors, the studies were repeated in
C57/BL6 mice challenged with B16-F10 tumor cells.
Therapy was initiated when these tumors reached
≈ 500 mm3 in volume. These cancers grow so rapidly
that they all reached the 2,000 mm3 endpoint in control
mice and had to be sacrificed in less than one wk
(Figure 6). The same endpoint was reached by all ani-
mals treated with a single TLR agonist within 2 wk. In
contrast, nearly 90% recipients (8/9) of the combination
therapy survived indefinitely, totally clearing their tu-
mors (Figure 6 and Additional file 5: Figure S4).
Composite
Table 1 Effect of TLR agonists on gene regulation in the tumor microenvironment
Mean fold-change in mRNA levels (vs PBS treated controls)
Gene CpG ODN + 3M control 3M-052 + CpG control CpG ODN + 3M-052
IL-12 2.23* ± 0.18 1.40 ± 0.19 3.39*** ± 0.11
INFγ 1.94* ± 0.15 1.87* ± 0.25 2.81** ± 0.24
Granzyme B 1.69* ± 0.07 1.87* ± 0.08 4.44*** ± 0.23
Arg1 1.01 ± 0.09 0.63* ± 0.09 0.43** ± 0.08
Nos2 1.83 ± 0.05 0.39** ± 0.04 0.09** ± 0.04
CTLA-4 0.85* ± 0.03 0.52** ± 0.01 0.33*** ± 0.02
TGFβ 0.43* ± 0.03 0.45* ± 0.01 0.26** ± 0.02
Mice were treated as described in Figure 1. mRNA was isolated from tumor infiltrating cells one day after the second treatment and analyzed by RT-PCR. Each
point represents the mean ± SD fold difference in cells from treated vs untreated tumor bearing mice derived from independently studying 6 mice/group in 2
independent experiments.
*, p < 0.05; **, p <0.01, ***, p <0.001 when compared to PBS treated controls. Note: the level of expression of all genes from mice treated with CpG ODN plus
3M-052 was also significantly different (p < .01 - 0.05) from that of mice treated with CpG ODN alone or 3M-052 alone.
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tumor-specific immunity was responsible for these cures.
First, lymphocytes were isolated from the draining LN of
mice challenged with CT26 tumors one week after the
initiation of therapy. These cells were then stimulated
in vitro with AH-1 peptide and their production of
IFNγ monitored. As in Figure 3, T cells from mice
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Figure 5 Effect of TLR agonists on large established CT26
tumors. 105 CT26 colon cancer cells were implanted into the flank
of syngeneic BALB/c mice. When the tumors reached ≈ 800 mm3 in
volume they were injected with 200 μg of CpG or control ODN and/
or 100 μg of 3M-052 or 3M control twice weekly for one month. The
change in tumor volume of 15 mice/group is shown (mean + SE).052 generated significantly stronger tumor specific re-
sponses that did any of the controls (p <.001, Figure 7A).
The twice weekly combination therapy with CpG
ODN plus 3M-052 was discontinued when tumors could
no longer be detected (generally after 1 month). There
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Figure 6 Effect of TLR agonists on large established B16-F10
tumors. 105 B16-F10 melanoma cancer cells were implanted into
the flank of syngeneic C57Bl/6 mice. When the tumors reached
≈ 500 mm3 in volume they were injected with 200 μg of CpG or
control ODN and/or 100 μg of 3M-052 or 3M control twice weekly
for one month. The change in tumor volume of 8 mice/group is















































































Figure 7 TLR agonist therapy induces persistent immunity. 105
CT26 cells were implanted into the flank of syngeneic BALB/c mice.
Large established tumors (≈800 mm3 in volume) were treated as
described in Figure 5. A) Cells from the tumor draining LN were
isolated one day after the third treatment, stimulated ex vivo with
AH-1 peptide, and monitored for IFNγ secretion by ELIspot assay.
Results represent the mean + SD of 4 independently studied mice/
group. B) Mice cured of their CT26 tumors by treatment with CpG
ODN plus 3M-052 (a cure being defined as being free of detectable
tumor for ≥2 months after the cessation of therapy) were re-
challenged with 106 CT26 cells. Their survival compared to naive
mice challenged with the same tumor dose is shown (N = 6 mice/
group). *, p < 0.05; **, p <0.01, ***, p <0.001.
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lasting tumor-specific immunity, they were re-challenged
with a 10-fold higher dose of CT26 cells. As seen in
Figure 7B, all of these animals survived whereas naive con-
trols perished.
Discussion
Individual TLR agonists can significantly improve the
host’s response to small tumors [34-36]. In the hope of
identifying a pairing of agonists that might be effective
against large established tumors, a number of TLR agon-
ist combinations were examined. Based on preliminary
studies, the combination of 3M-052 plus CpG ODN was
selected for further analysis. The anti-tumor activity of
CpG ODN includes i) the stimulation of pDC that
improve the generation of tumoricidal NK and CD8 T
cells and ii) triggering MDSC to differentiate into M1
macrophages that no longer mediate immune suppres-
sion [19,20,22,37,38]. TLR 7/8 agonists also support the
induction of cancer-specific immunity by triggering an
innate response characterized by the production of Th1 cy-
tokines (including TNFα, IL-12, and IFNγ) and DC matur-
ation [39]. Of interest, TLRs 7, 8 and 9 are expressed on
different subsets of immune cells that together include T
cells, DCs, NK and NKT cells, all of which contribute to
anti-tumor activity [40,41].
Whereas many forms of immunotherapy are effective
against small tumors (<300 mm3), activity wanes when
larger tumors are targeted. A number of factors contrib-
ute to the resistance of established tumors. In addition
to challenging the immune system with a larger number of
target cells, organized tumors are better able to cloak them-
selves in immunosuppressive Tregs and MDSC [42,43]. In
this context, MDSC from patients with advanced tumors
are particularly effective at inhibiting tumor-specific CD8 T
cells [44]. Having found that intra-tumoral delivery of CpG
ODN was considerably more effective than systemic ad-
ministration for the treatment of tumors, our plan was to
examine whether adding a TLR 7/8 agonist could further
improve this therapeutic approach. Unfortunately, first gen-
eration TLR 7/8 agonists were water soluble and proved
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tively new TLR 7/8 agonist was identified that contains a
modified tail allowing it to persist in vivo after being
injected into the tumor (3M-052) [23]. Further studies
therefore evaluated the activity of locally administered 3M-
052 in combination with CpG ODN.
The value of combination therapy was initially exam-
ined under conditions where a single TLR agonist only
delayed tumor growth (Figure 1). Large tumors were
then studied in which the combination of CpG ODN
plus 3M-052 proved highly successful against both CT26
colon cancer and B10-F16 melanomas. Whereas each
agonist alone barely delayed the progression of these
large tumors, cure rates on the order of 80 - 90% were
achieved by combination therapy. Indeed, as weeping of
the injected material from the tumor site was sometimes
observed, it is possible that even higher success rates
might be achieved by technical improvements in TLR
agonist delivery. Successful therapy of large tumors
required twice-weekly treatment with CpG ODN plus
3M-052 over the course of ≈ 1 month. A single dose had
no detectable effect on the growth of large tumors while
1–2 wks of combination therapy resulted in only short-
lived tumor regression. Systemic treatment was uniformly
unsuccessful.
There are several mechanisms by which TLR agonists
can support the elimination of established tumors. CD28
is a co-stimulatory molecule that enhances the prolifera-
tion, cytokine production and survival of TCR-activated
T cells. This process is antagonized by CTLA-4, a sur-
face receptor that is up-regulated when T cells become
activated [30,31]. We observed that the level of mRNA
encoding CTLA-4 was significantly reduced in mice re-
ceiving combination therapy (Table 1). This down-
modulation of CTLA-4 may help explain the improved
activity of tumor-specific T cells found in the current
work (Figure 3), consistent with previous findings [45].
We also observed a decrease in mRNA encoding the im-
munosuppressive cytokine TGFβ in mice treated with
CpG ODN plus 3M-052. TGFβ is produced by tumor
cells and Gr-1+ CD11b+MDSC in the tumor micro-
environment and serves to suppress both innate and
adaptive arms of the immune system [29,46,47]. Consist-
ent with current findings, reduced TGFβ signaling is
known to enhance tumor elimination by improving CTL
activity [32,33].
To establish the role of increased CTL function in recipi-
ents of combination therapy, cells from the tumor draining
lymph node were isolated and stimulated ex vivo with the
CT26-specific AH-1 peptide. While CpG ODN and
3M-052 alone boosted the number of cells secreting
IFNγ, significantly more cells from recipients of combin-
ation therapy were stimulated to produce that cytokine
(Figures 3 and 7A). Consistent with the conclusion thatthese cells contribute to tumor eradication, the level of
mRNA encoding cytokines that promote Th1 and cellular
immunity (IL-12 and IFNγ) and the lytic activity of NK
and CD8 T cells (granzyme B) were all significantly up-
regulated in the tumor microenvironment (Table 1) as
were the number of tumor infiltrating CD8 T cells and
NK cells (Figure 2).
Despite the above findings, the mechanism(s) by which
engagement of TLRs 7, 8 and 9 synergistically enhance
anti-tumor immunity will require further investigation.
Since all three TLRs utilize the MyD88 dependent sig-
naling pathway, it might seem unlikely that cells express-
ing receptors for all three agonists could be responsible
for such synergy (as any single TLR agonist would be
sufficient to trigger such cells). Yet recent studies of
TLR expression by individual pDC indicates that pheno-
typically identical cells nevertheless express very differ-
ent levels of each receptor, and that engagement of
multiple receptors may be necessary to reach a critical
activation threshold. Moreover, certain cells express TLR
7 or 8 but not TLR 9 (such as iNKT cells) while MDSC
express high levels of TLR 9 but only low levels of TLR
7/8 [22,48].
Other examples of TLR synergy have been observed. For
example, co-delivery of the TLR3 agonist poly A:U induced
an effective anti-tumor response when used in combination
with CpG ODN under conditions when each agonist alone
was ineffective [49]. It was also shown that combinations of
TLR 2, 3 and 9 ligands could enhance DC function and the
induction of T cell immunity following vaccination [50].
Finally, a DC based vaccine delivered with TLR3 and TLR 2
provided enhanced protection to mice challenged with
tumor [51].
A number of clinical trials have explored the activity
of CpG ODN in cancer patients. Results indicate that
CpG treatment induces a dose-related increase in serum
levels of IP-10, IFNa, MIP-1a, and IL-12p40 [52,53].
While anti-tumor activity was observed in several phase
II trials [54] this finding was not reproduced in a defini-
tive phase III study [55,56]. Of note, none of these
studies combined CpG ODN with a TLR7/8 agonist and
generally administered the ODN systemically rather
intra-tumorally. We postulate that the local delivery of
combination TLR 7/8/9 agonists is critical for improving
the host’s anti-tumor response by acting on multiple cell
types in the tumor microenvironment, including mMDSC,
CD8 T lymphocytes and NK cells. Of interest, MDSC ex-
press receptors for both agonists and play a vital role pro-
tecting tumors from immune aggression by inhibiting T
and NK cell activity [22,57]. Current findings demonstrate
that the combination of CpG ODN plus 3M-052 reduced
mMDSC frequency by 10-fold when compared to un-
treated mice and 3–5 fold when compared to either
agonist alone (Figure 2). This reduction was associated
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(Table 1), a constellation of findings that may explain the
increase in tumor-specific CTL activity in mice treated with
combination therapy (Figures 3 and 7A).
Conclusions
This work shows that co-administering CpG ODN with
3M-052 is remarkably effective at eliminating large
established tumors. This anti-tumor activity is associated
with a significant diminution in the frequency of tumor
resident MDSC and accumulation of tumor-lytic NK
and CD8 T cells, resulting in persistent anti-tumor im-
munity. These findings indicate that combination TLR




3M-052 was supplied by 3M Drug Delivery Systems
Division as a 4 mg/ml stock solution in ethanol.
Endotoxin-free phosphorothioate ODN were synthe-
sized at the Core Facility of the Center for Biologics
Evaluation and Research, Food and Drug Administra-
tion (Bethesda, MD). The sequences used were: CpG
ODN 1555 (5′-GCTAGACGTTAGCGT-3′) and control
ODN 1612 (5′-GCTAGAGCTTAGCGT-3′). All ODN
were dissolved in PBS at a final concentration of 4 mg/ml.
Mice and tumor cell lines
6–8 wk old BALB/c and C57BL/6 mice were obtained
from the National Cancer Institute (Frederick, MD). The
CT26 colon cancer cell line was a kind gift from Dr.
Zack Howard (National Cancer Institute) and B16-F10
cell line was purchased from American Type Culture
collection (Manassas, VA). Tumor cell lines were main-
tained in RPMI 1640 medium supplemented with 10%
FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 25 mM
HEPES, 1.0 mM sodium pyruvate, nonessential amino
acids, and 0.0035% 2-ME. All studies were approved by the
National Cancer Institute Frederick Animal Care and Use
Committee.
Tumor experiments
Balb/c mice were injected with 105 CT26 tumor cells
while C57BL/6 mice received 105 B16-F10 tumor cells.
All injections were s.c. into the right flank. Treatment
was initiated when tumors reached a defined size (usu-
ally after 2–3 wk). Tumor size was calculated by the for-
mula: (length × width × depth)/2 and mice whose tumor
exceeded a diameter of 2.0 cm were euthanized as per
ACUC regulations. Two treatment regimens were used.
For small tumors (<300 mm3), two doses of 100 μg of
CpG ODN (4 mg/ml) and/or 50 μg of 3M-052 (4 mg/
ml) were injected intra-tumorally using a 30 g needle.To deplete CD4+ or CD8+ T cell subsets, mice were
injected i.p. with 25 ul ascites of rat anti-mouse CD4
(L3/T4) or mouse anti-mouse CD8 (Ly2.2) Abs from
Cedarlane labs (Burlington, NC) on day −2, 0, 3 and
6 post-tumor implantation. For large tumors (500–
800 mm3), 200 μg of CpG ODN and/or 100 μg of 3M-
052 were injected intra-tumorally twice weekly for one
month. Inactive controls for each TLR agonist were in-
cluded in all experiments. Tumor growth curves were
generated from five mice per group and all results were
derived by combining data from 2–3 independent
experiments.
Flow cytometric analysis
Leukocytic infiltrates of the tumor site were prepared
by surgical removal of tumor tissue followed by
homogenization using a GentleMACS Dissociator (Miltenyi
Biotec) and then digestion in RPMI containing 5% fetal calf
serum, 250 U/mL type IV collagenase (Invitrogen) and
100 mg/mL DNase I (Roche Molecular Biochemicals) at
37°C for 30 minutes. The resulting single cell suspension
was passed through a 70 µm cell strainer (BD Biosciences,
Bedford, MA), and washed twice with RPMI. Live cells
were isolated by density gradient centrifugation (Histopa-
que-1077, Sigma-Aldrich), washed, and stained using the
following Abs from BD Pharmingen (clone names provided
in parentheses). CD11b (M1/70) and Gr-1 (RB6-8C5) for
MDSC, CD3 (145-2C11) and CD8 (53–6.7) for T cells and
CD49b (DX5) for NK cells. CD45 (30-F11) was used as a
leukocyte marker. Stained cells were analyzed using an
LSR-II flow cytometer (Becton Dickinson).
ELISpot assay
Single cell suspensions were prepared from whole spleen,
tumor-infiltrating leukocytes or tumor draining lymph
nodes and 1.5 - 3.0 × 105 cells/well stimulated for 12 hr
with the class-I restricted CT26-derived AH-1 peptide
(1 ug/ml) in 96 well Immulon II plates (Millipore, Billerica,
MA) coated with anti-IFN Ab (R4-6A2) (BD Biosciences).
The plates were washed and treated with biotinylated poly-
clonal goat anti-IFNγ Ab (R & D systems, MN) followed by
streptavidin alkaline phosphatase. Spots were visualized by
the addition of a 5-bromo-4-chloro-3-indolyl phosphatase
solution (Sigma Aldrich) in low melt agarose (Sigma
Aldrich) and counted manually under ×40 magnification.
The number of cytokine secreting cells was determined by
a single blind reader, and all data was generated by analyz-
ing 12 separate wells per sample.
Quantitative real-time PCR analysis
Total RNA was isolated from tumor infiltrating cells one
day after the second treatment using TRIzol reagent
(Invitrogen), precipitated, and then reverse transcribed
with Reverse Transcription Kit (Qiagen). IL-12p40, IFNγ,
Zhao et al. Journal for ImmunoTherapy of Cancer 2014, 2:12 Page 9 of 10
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levels were examined using the TaqMan Gene Expres-
sion Master Mix and the StepOne RT-PCR system
(Applied Biosystems, Foster City, CA). All primer sets
were from Applied Biosystems. Gene expression was
normalized to the level of the GAPDH housekeeping
gene. Data were analyzed by StepOne software (Applied
Biosystems) and expressed as a fold change in mRNA
expression relative to control values. Ct values for all
genes studied fell in the range of 22–35.
Statistical analysis
P values for each experimental group were determined
by comparison to the PBS control group using an un-
paired student’s t test.
Additional files
Additional file 1: Figure S1. In vivo persistence of 3M-052. Serum
levels of 3M-052 and Resiquimod were measured at multiple time points
after subcutaneous administration of 1 mg/Kg of each agent. Blood was
collected before and at various time post delivery. % maximal serum
concentration was calculated by the formula: serum level/maximum
serum level × 100%. Results represent the mean of 5 independently
studied animals/group.
Additional file 2: Table S1. HEK293 cells were stably transfected to
express human TLR7 or TLR8. Cells were cultured in 24 well plates at 106
cells/mL and treated with 3 µM of 3M-052, Resiquimod, or vehicle (0.33%
DMSO). IL-8 levels in culture supernants were measured after 16 hr by
ELISA. Results show the mean ± SD of 3 independent cultures.
Additional file 3: Figure S2. Gating strategy used to identify the
immune cells. Single cell suspensions were prepared as described in the
Methods section. Live cells isolated by density gradient centrifugation
were stained and analyzed using an LSR-II flow cytometer. The gates
used to identify specific cell subpopulations are shown.
Additional file 4: Figure S3. TLR agonist therapy does not affect Treg
frequency. Mice were treated as described in Figure 1. The frequency
of tumor-infiltrating Treg was determined one day after the second
treatment by staining for Foxp3+ cells. Results show the mean + SD of
as a percentage of total CD45+ tumor infiltrating cells analyzed independently
in 6 mice from 2 independent experiments.
Additional file 5: Figure S4. Effect of TLR agonists on large established
tumors. Survival curves are provided for mice challenged with CT26
colon cancer cells (A) or B16-F10 melanoma cancer cells (B) and treated
with 200 μg of CpG or control ODN and/or 100 μg of 3M-052 or 3M
control twice weekly for one month as described in Figures 4 and 5.
**; p < .01 vs all 3 control groups.
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CTL: Cytotoxic T cell; DC: Dendritic cell; MDSC: Myeloid derived suppressor
cell; ODN: Oligonucleotide; PAMP: Pathogen-associated molecular pattern;
TLR: Toll-like receptor.
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